Advanced Drug Delivery Systems Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

The Report Covers Global Drug Delivery Systems Market Share & Trends. The Market is Segmented by Type (Oral Drug Delivery System, Injection-based Drug Delivery System, Inhalation/Pulmonary Drug Delivery System, Transdermal Drug Delivery System, Transmucosal Drug Delivery System, Carrier-based Drug Delivery System, and Other Types), Application (Cardiovascular Diseases, Oncology, Urology, Diabetes, Central Nervous System, Ophthalmology, Infections, Other Applications), Technology (Prodrug, Implants and Intrauterine Devices, Targeted Drug Delivery, Polymeric Drug Delivery, and Other Technologies), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The value is provided in (USD million) for the above segments.

Advanced Drug Delivery Systems Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

Advanced Drug Delivery Systems Market Size

Advanced Drug Delivery Systems Market Summary
Study Period 2019 - 2030
Base Year For Estimation 2024
Forecast Data Period 2025 - 2030
Historical Data Period 2019 - 2023
CAGR 5.30 %
Fastest Growing Market Asia Pacific
Largest Market North America

Major Players

Advanced Drug Delivery Systems Market Major Players

*Disclaimer: Major Players sorted in no particular order

Compare market size and growth of Global Advanced Drug Delivery Systems Market with other markets in Healthcare Industry

Biotechnology

Pharmaceuticals

Healthcare IT

Medical Devices

Animal Health

Device Drug Combination

Advanced Drug Delivery Systems Market Analysis

The Global Advanced Drug Delivery Systems Market is expected to register a CAGR of 5.3% during the forecast period.

The COVID-19 pandemic had positively impacted the market's growth rate. Several studies emphasize how ADDS will help develop improved delivery systems (dosage forms) of existing therapeutic agents. For instance, in June 2020, the Chalmers University of Technology in Sweden, the University of Gothenburg, and AstraZeneca started new pivotal research combining many promising concepts to investigate a nasal spray mRNA vaccine against COVID-19. The team was working on a biomimetic nanoparticle that contains both immune enhancers and a targeting protein to investigate design principles for nasal immunization. The Chalmers Innovation Office, the Chalmers Area of Advance Health Engineering, the Swedish Foundation for Strategic Research, and the Swedish Research Council contributed to the initiative.

Additionally, in April 2020, Bioavanta-Bosti developed a 48-hour manufacturing process using its Novochizol chitosan polysaccharide nanotechnology to encapsulate APIs or biologics for localized delivery and sustained release intra-pulmonary drug delivery formulations, which are suitable for treating COVID-19 patients. Bioavanta-Bosti also reported in 2020 that it is looking for collaborations with drug developers and clinical researchers to produce a repurposed medicine or new molecular or biological entity formulations to treat severe COVID-19 infection in the lungs. ADDS has aided in exploring new insights to identify untapped areas for future targeted distribution, and it is quickly gaining traction in the pharmaceutical sector and academic institutions. Thus, COVID-19 has had a significant impact on the growth of the market.

Furthermore, the factors driving this market's growth include the development of new drugs and biologics; advancements in understanding human biology and diseases; and increased R&D spending.

Advancements in several biology-oriented initiatives have created a unique opportunity to better understand the molecular effects of human diseases and develop novel drugs and biologics based on these factors. The recently discovered advanced drug delivery systems include lipid, protein, and polymer technologies with better lipid distribution in the body, preventing drug degradation due to the external environment and reducing the rate of drug clearance. Advanced drugs and biologics have higher efficiency with a smaller dosage of drugs. Hence, they must be supported with advanced drug delivery systems to gain maximum efficacy.

In addition to the drugs and biologics, the drug-eluting implants have the potential to provide uninterrupted treatment and a reduction in drug dosage (hence a less frequent need for dosing). The advanced sustained release systems help target intestinal infections and others. The trend toward self-injection devices and the rapidly growing pipeline of biologics/biosimilars and auto-injectors have also recently emerged as an important class of medical devices. Many companies are focusing on the launch of new products that will contribute to market growth. For instance, in December 2020, Agile Therapeutics, Inc., commercially launched Twirla (levonorgestrel and Ethinyl estradiol) transdermal system, a new non-daily, non-invasive contraceptive patch in the United States. Additionally, in February 2022, Nu Gen Medical Devices Inc. delivered a purchase order from a Taiwanese medical distributor, Shin-Ya Biotechnology Co., Ltd., for its InsuJet needleless injection system. This is part of a multi-year sales and distribution agreement with a minimum commitment of CDN 100,000 over the first two years, with future commitments for the remaining three years of the agreement to be finalized in due course. Such agreements are also contributing to the growth of the market.

Likewise, Duocap (capsule-in-a-capsule), electrocapsule, and light-up delivery monitoring technology (LDMT) are some of the controlled and targeted oral drug delivery systems that provide a new way of formulating poorly soluble compounds and monitoring the release rate of drugs. Advanced drug delivery systems are being developed to resolve solubility problems and make the drugs more lipid-soluble. Thus, this enables them to easily cross lipid barriers in the body, eventually preventing external issues, such as photodegradation and pH changes, from affecting the drug and further achieving the desired concentration at the desired location to provide the maximum therapeutic effect. Thus, these developments are expected to positively impact the market's growth.

However, product recalls of advanced drug delivery products and challenges in nanomedicine-based drug delivery may hinder the growth of the market.

Advanced Drug Delivery Systems Industry Overview

The advanced drug delivery systems market is moderately competitive. Owing to the continuous technological advancements in the drug delivery system, there are possibilities for newer players to enter the market over the coming years. Some major players in this market are Boston Scientific Corporation, Baxter International, Becton, Dickinson and Company, Kindeva Drug Delivery L.P., and others.

Advanced Drug Delivery Systems Market Leaders

  1. Boston Scientific Corporation

  2. Becton, Dickinson and Company

  3. AbbVie Inc.

  4. Kindeva Drug Delivery L.P.

  5. Baxter

  6. *Disclaimer: Major Players sorted in no particular order
Advanced Drug Delivery Systems Market Concentration
Need More Details on Market Players and Competiters?
Download PDF

Advanced Drug Delivery Systems Market News

  • In March 2022, Corium, Inc. received United States Food and Drug Administration (FDA) approval for Corium's ADLARITY (donepezil transdermal system) as a treatment for patients with mild, moderate, or severe dementia of the Alzheimer's type. ADLARITY is one of the first and only once-weekly patches to continuously deliver consistent doses of donepezil through the skin.
  • In March 2022, the United States Food and Drug Administration approved the first generic of Symbicort (budesonide and formoterol fumarate dihydrate) Inhalation Aerosol for the treatment of two common pulmonary health conditions: asthma in patients six years of age and older; and chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.

Advanced Drug Delivery Systems Market Report - Table of Contents

1. INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Development of New Drugs and Biologics
    • 4.2.2 Advancements in Understanding Human Biology and Diseases
    • 4.2.3 Increased R&D Spending
  • 4.3 Market Restraints
    • 4.3.1 Product Recalls of Advanced Drug Delivery Products
    • 4.3.2 Challenges in Nanomedicine-based Drug Delivery
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5. MARKET SEGMENTATION (Market Size by Value - USD million)

  • 5.1 By Type
    • 5.1.1 Oral Drug Delivery System
    • 5.1.2 Injection-based Drug Delivery System
    • 5.1.3 Inhalation/Pulmonary Drug Delivery System
    • 5.1.4 Transdermal Drug Delivery System
    • 5.1.5 Trans mucosal Drug Delivery System
    • 5.1.6 Carrier-based Drug Delivery System
    • 5.1.7 Other Types
  • 5.2 By Application
    • 5.2.1 Cardiovascular Diseases
    • 5.2.2 Oncology
    • 5.2.3 Urology
    • 5.2.4 Diabetes
    • 5.2.5 Central Nervous System
    • 5.2.6 Ophthalmology
    • 5.2.7 Infections
    • 5.2.8 Other Applications
  • 5.3 By Technology
    • 5.3.1 Prodrug
    • 5.3.2 Implants and Intrauterine Devices
    • 5.3.3 Targeted Drug Delivery
    • 5.3.4 Polymeric Drug Delivery
    • 5.3.5 Other Technologies
  • 5.4 Geography
    • 5.4.1 North America
    • 5.4.1.1 United States
    • 5.4.1.2 Canada
    • 5.4.1.3 Mexico
    • 5.4.2 Europe
    • 5.4.2.1 Germany
    • 5.4.2.2 United Kingdom
    • 5.4.2.3 France
    • 5.4.2.4 Italy
    • 5.4.2.5 Spain
    • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
    • 5.4.3.1 China
    • 5.4.3.2 Japan
    • 5.4.3.3 India
    • 5.4.3.4 Australia
    • 5.4.3.5 South Korea
    • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle-East and Africa
    • 5.4.4.1 GCC
    • 5.4.4.2 South Africa
    • 5.4.4.3 Rest of Middle-East and Africa
    • 5.4.5 South America
    • 5.4.5.1 Brazil
    • 5.4.5.2 Argentina
    • 5.4.5.3 Rest of South America

6. COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Becton, Dickinson and Company
    • 6.1.2 Abbott Laboratories
    • 6.1.3 Baxter
    • 6.1.4 Bayer AG
    • 6.1.5 Boston Scientific Corporation
    • 6.1.6 Kindeva Drug Delivery L.P.
    • 6.1.7 Johnson & Johnson
    • 6.1.8 Pfizer Inc.
    • 6.1.9 Novartis AG
    • 6.1.10 Medtronic
    • 6.1.11 Ypsomed
    • 6.1.12 Abbvie, Inc.
    • 6.1.13 Astrazeneca
  • *List Not Exhaustive

7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Advanced Drug Delivery Systems Industry Segmentation

As per the scope of the report, advanced drug delivery systems are improved methods for delivering the drug molecule to the targeted site in a more controlled manner. These methods are being developed to improve the efficacy ratio of the currently available drugs. Delivering drugs at a controlled rate, slow and targeted delivery for onsite drug release and absorption is the basis for developing advanced drug delivery systems. The Advanced Drug Delivery Systems Market is segmented by Type (Oral Drug Delivery System, Injection-based Drug Delivery System, Inhalation/Pulmonary Drug Delivery System, Transdermal Drug Delivery System, Transmucosal Drug Delivery System, Carrier-based Drug Delivery System, and Other Types), Application (Cardiovascular Diseases, Oncology, Urology, Diabetes, Central Nervous System, Ophthalmology, Infections, Other Applications), Technology (Prodrug, Implants, and Intrauterine Devices, Targeted Drug Delivery, Polymeric Drug Delivery, and Other Technologies), and Geography (North America, Europe, Asia-Pacific, Middle East, and Africa, and South America). The report offers the value (USD million) for the above segments. The market report also covers the estimated market sizes and trends for 17 countries across major global regions.

By Type Oral Drug Delivery System
Injection-based Drug Delivery System
Inhalation/Pulmonary Drug Delivery System
Transdermal Drug Delivery System
Trans mucosal Drug Delivery System
Carrier-based Drug Delivery System
Other Types
By Application Cardiovascular Diseases
Oncology
Urology
Diabetes
Central Nervous System
Ophthalmology
Infections
Other Applications
By Technology Prodrug
Implants and Intrauterine Devices
Targeted Drug Delivery
Polymeric Drug Delivery
Other Technologies
Geography North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle-East and Africa GCC
South Africa
Rest of Middle-East and Africa
South America Brazil
Argentina
Rest of South America
Need A Different Region or Segment?
Customize Now

Advanced Drug Delivery Systems Market Research FAQs

What is the current Global Advanced Drug Delivery Systems Market size?

The Global Advanced Drug Delivery Systems Market is projected to register a CAGR of 5.3% during the forecast period (2025-2030)

Who are the key players in Global Advanced Drug Delivery Systems Market?

Boston Scientific Corporation, Becton, Dickinson and Company, AbbVie Inc., Kindeva Drug Delivery L.P. and Baxter are the major companies operating in the Global Advanced Drug Delivery Systems Market.

Which is the fastest growing region in Global Advanced Drug Delivery Systems Market?

Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).

Which region has the biggest share in Global Advanced Drug Delivery Systems Market?

In 2025, the North America accounts for the largest market share in Global Advanced Drug Delivery Systems Market.

What years does this Global Advanced Drug Delivery Systems Market cover?

The report covers the Global Advanced Drug Delivery Systems Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Global Advanced Drug Delivery Systems Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.

Advanced Drug Delivery Systems Industry Report

Statistics for the 2025 Global Advanced Drug Delivery Systems market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Global Advanced Drug Delivery Systems analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.